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Vaccination with exogenous antigens such as recombinant viral proteins, immunodeficiency virus-derived whole inactivated virus particles, or
virus-like particles (VLP) has generally failed to provide sufficient protection in animal models for AIDS. Pseudotyping VLPs with the vesicular
stomatitis virus G protein (VSV-G), which is known to mediate entry into dendritic cells, might allow more efficient stimulation of immune
responses. Therefore, we pseudotyped noninfectious immunodeficiency virus-like particles with VSV-G and carried out a preliminary screen of
their immunogenicity and vaccination efficacy. Incorporation of VSV-G into HIV-1 VLPs led to hundred-fold higher antibody titers to HIV-1 Gag
and enhancement of T cell responses in mice. Repeated vaccination of rhesus monkeys for 65 weeks with VSV-G pseudotyped simian
immunodeficiency virus (SIV)-like particles (VLP[G]) provided initial evidence for efficient suppression of viral load after mucosal challenge
with the SIVmac239 virus. Challenge of monkeys after a 28 week vaccination regimen with VLP[G] led to a reduction in peak viremia, but
persistent suppression of viral load was not achieved. Due to limitations in the number of animals available for this study, improved efficacy of
VSV-G pseudotyped VLPs in nonhuman primates could not be demonstrated. However, mouse experiments revealed that pseudotyping of VLPs
with fusion-competent VSV-G clearly improves their immunogenicity. Additional strategies, particularly adjuvants, should be considered to
provide greater protection against a challenge with pathogenic immunodeficiency virus.
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With HIV spreading worldwide, the need for a preventive or
therapeutic vaccine is more urgent than ever before. Efficacy
studies in humans require large cohorts, and only two phase-III
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doi:10.1016/j.virol.2006.03.009performed that gave no evidence of protection. Therefore, most
of our knowledge on the efficacy of HIV vaccines comes from
animal models, particularly the infection of macaques with
simian immunodeficiency viruses (SIV). Work on live attenu-
ated immunodeficiency viruses in nonhuman primate models
has shown that a vaccine can provide protection from
progression to AIDS even in the absence of a sterilizing
immunity (Daniel et al., 1992; Marthas et al., 1990). A number
of effector mechanisms, including neutralizing antibodies and
134 S. Kuate et al. / Virology 351 (2006) 133–144CD8+ cytotoxic T lymphocytes, are likely to contribute to
protection (reviewed in Johnson, 2002). In addition to the live-
attenuated vaccines, which for safety reasons are unlikely to be
applicable in humans, a number of nonreplicating or exogenous
vaccine approaches have been studied in the SIV macaque
model. However, vaccination with recombinant Env proteins
does not provide sufficient protection against pathogenic SIV
(Giavedoni et al., 1993; Lu et al., 1998) consistent with results
from the human phase III trials (Flynn et al., 2005). Similarly,
whole inactivated SIV vaccines and virus-like particles do not
provide significant protection if the challenge virus is grown in
monkey cells (Le Grand et al., 1992; Notka et al., 1999; Stott,
1991). A common feature of vaccination with recombinant viral
proteins and whole inactivated viruses is injection of exogenous
antigens, which predominantly leads to MHC-II-restricted
cellular immune responses and production of antibodies. In
contrast, some virus-like particles of HIV or SIV also induced
CTL responses (Deml et al., 1997; Paliard et al., 2000).
We and others have previously generated single cycle
immunodeficiency viruses (SCIVs) that can undergo only a
single round of replication leading to the production of
noninfectious virus-like particles in the vaccinees (Evans et
al., 2004; Kuate et al., 2003). After booster immunizations with
SCIVs, SIV-specific humoral and cellular immune responses
were observed and peak viremia during primary infection with
the SIVmac239 challenge virus was significantly reduced
(Evans et al., 2005; Kuate et al., 2003). To increase in vivo
expression levels, we pseudotyped the single cycle immunode-
ficiency virus (SCIV) vaccines with VSV-G. VSV-G mediates
efficient entry into a broad spectrum of cells (Burns et al., 1993)
including dendritic cells (Granelli-Piperno et al., 2000) and is
therefore frequently used in gene transfer experiments with
lentiviral and retroviral vectors. VSV-G has also been shown to
enhance the immunogenicity of an HIV-gag DNA vaccine if
coexpressed with the antigen (Marsac et al., 2002). We now
analyzed the influence of VSV-G on the immunogenicity of
virus-like particles and compared VSV-G pseudotyped, non-
replicating VLPs (VLP[G]) of SIV to SCIV vaccines to
determine whether expression of viral antigens in the vaccinee
improves immunogenicity and protective efficacy. We provide
initial evidence that in vivo expression of viral antigens by
SCIVs is not required for the protective properties observed and
show that incorporation of VSV-G into noninfectious VLPs
enhances humoral and cellular immune responses.
Results
In previous experiments, monkeys immunized with VSV-G
pseudotyped single cycle immunodeficiency virus vaccines
(SCIV) showed SIV-specific humoral and cellular immune
responses and peak viremia during primary infection with the
SIVmac239 challenge virus was significantly reduced (Kuate et
al., 2003). Restriction of SCIVs to a single round of in vivo
expression of viral antigen was achieved by mutating the primer
binding site of SIV and complementation of these mutations by
cotransfection of an expression plasmid encoding a matched
artificial tRNA during vaccine production (Kuate et al., 2003).Omitting the tRNA expression plasmid during vaccine
production results in noninfectious VLPs that do not differ in
protein composition from the SCIVs (Kuate et al., 2003). Since
it remained unclear, whether in vivo expression of viral antigens
by SCIVs is indeed beneficial, we now performed a
comparative analysis of VSV-G pseudotyped SIV particles in
an infectious (SCIV) and noninfectious virus-like particle (VLP
[G]) form. SCIVs were produced as described previously
(Kuate et al., 2003) by cotransfection of SIV genomic DNA
with mutations in the primer binding site and deletions in
accessory genes with a VSV-G expression plasmid and the
tRNA expression plasmid. For production of VLP[G], the same
mutated SIV-DNA and VSV-G expression plasmid were
cotransfected, but the tRNA expression plasmid was omitted.
Omitting the tRNA expression plasmid does not affect the
protein composition of the particles, but reduces the infectivity
of such particles below the level of detection (Kuate et al.,
2003).
Monkeys were immunized by seven subcutaneous injections
of 107 infectious units of SCIV at week 0, 4, 8, 29, 33, 37, and
65. Since the ratio of infectious units to the amount of viral
proteins can vary between different preparations, the amount of
reverse transcriptase in the SCIV preparations was used as a
measure of viral antigen content. The dose of the VLP[G] was
always adjusted by its content of reverse transcriptase. Thus,
both groups received approximately equal amounts of exoge-
nous viral antigens, but only the SCIV-injected monkeys should
also express the viral antigens themselves. An additional group
of two monkeys did not receive any exogenous viral antigens,
but was immunized with a DNA vaccine encoding SIV
structural proteins and Tat and Rev. To increase in vivo
expression levels of the DNA vaccine, it was complexed with
cationic lipids. Monkeys of a fourth group served as
nonvaccinated controls.
During immunization, SCIV and VLP[G] immunized
monkeys developed similar titers of antibodies to Gag, while
the Env antibody response seemed to be stronger in SCIV
immunized monkeys (Figs. 1B, D). However, the antibodies to
Env induced by vaccination did not neutralize homologous
SIVmac239 even at a 1:10 dilution of serum (Fig. 2B). In
contrast, neutralization of the closely related SIVmac251 virus
was readily detectable at a 1:100 dilution of serum (Fig. 2D).
Neutralizing antibodies against VSV-G were also detectable
(Fig. 2A), but they did not seem to prevent the booster effect of
repeated injections of VLP[G] or SCIV on humoral immune
responses. The lipid–DNA-immunized monkeys and the naive
control monkeys showed no antibody response at all (Figs. 1 A,
C). Results of an IFN-γ ELISPOT assay after stimulation with
an overlapping SIV Gag peptide pool are shown in Figs. 1E and
F. Two weeks after the last booster immunization, a strong
ELISPOT response was seen in the SCIV and VLP[G]-
immunized monkeys, but not in the lipid–DNA immunized
monkeys. Therefore, VSV-G-pseudotyped SIV particles in an
infectious (although only a single cycle) and noninfectious form
are immunogenic without additional adjuvants. However,
repeated immunizations seemed to be necessary for the
induction of detectable cellular immune reactions, since the
Fig. 1. Monkeys were immunized on weeks 0, 4, 8, 29, 33, 37, and 65 with SCIVor VLP[G] preparations normalized for RT activity. A third group received a lipid–
DNAvaccine while a forth group was left untreated (control). Antibody titers to SIV Gag (A, B), SIV Env (C, D), and IFN-gamma ELISPOT response after stimulation
with an overlapping SIV Ca peptide pool (E, F) were determined at the indicated time points after the 1st immunization. The arrow marks the time point of the last
booster immunization, the dotted line separates the data obtained before and after challenge at 69 weeks after the first immunization. The three-digital numbers indicate
the individual macaques.
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at earlier time points were generally weak and rather variable
(data not shown).
Four weeks after the last immunization, monkeys were
challenged with SIVmac239 by the tonsillar route, thus
providing a mucosal challenge with a stringent form of SIV.
All eight animals became infected, although peak viremia
was ∼20-fold lower in the SCIV and VLP[G]-immunized
monkeys (Fig. 3). Importantly, the viremia rapidly dropped
below the level of detection in SCIV and VLP immunized
monkeys (two animals each) and remained low except, for
one animal (macaque 927 SCIV), up to 95–117 weeks afterinfection (Figs. 3A, B). In contrast, lipid–DNA immunized
monkeys and the control monkeys maintained high viral
loads throughout the observation period. A similar pattern
was observed in the cell-associated viral load. However, the
last time points analyzed indicate a progressive increase of
virus load in both SCIV- and one of the VLP[G]-immunized
monkeys (Fig. 3D). The decline in the percentage of CD4+
T cells (Fig. 3E) in the control group indicated immune
dysfunction. One control monkey (macaque 928 control)
progressed to AIDS and had to be euthanized 62 weeks
after infection due to severe Pneumocystis carinii pneumonia
and a pharyngeal lymphoma. Three of the four monkeys
Fig. 2. Neutralizing antibodies against VSV-G (A), SIVmac239 Env (B), and SIVmac251 Env (C, D) at a 1/100 (A, C, D) or a 1/10 dilution (B) of sera obtained from
the monkeys at the indicated time points after the first immunization with week 69 being the time of challenge.
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(Fig. 3F) and remained healthy up to 120 weeks after
infection. One of the SCIV-immunized monkeys (927 SCIV)
showed a progressive decline in the percentage of CD4+ T
cells, consistent with increasing viral load levels in this
monkey.
The control of SIVmac239 replication in monkeys
vaccinated with VSV-G pseudotyped VLPs was striking
given the prior reports of inefficacy of whole inactivated
viruses and conventional VLPs lacking VSV-G (Le Grand et
al., 1992; Lu et al., 1998; Stott, 1991), including our own
experience (Notka et al., 1999). To determine if incorpora-
tion of VSV-G into VLPs enhances antiviral immune
responses, mice were immunized with HIV-1 VLPs, which
allowed monitoring of cellular immune responses with
immunodominant HIV-1 peptides. VSV-G pseudotyped
HIV-VLPs (VLPH[G]) or nonpseudotyped VLPs (VLPH)
were prepared by transient tranfection and pelleting through a
20% sucrose cushion. In addition, VLPs were prepared con-
taining a fusion-defective mutant of VSV-G (VLPH[Gmut]).
Western blot analyses with antibodies to HIV-1 Gag or Env
revealed similar amounts of both proteins for all preparations
(Fig. 4A). Similar amounts of wild type and fusion-defective
VSV-G were also detected in the VLPH[G] and VLPH[Gmut]
preparations (Fig. 4A). Balb/C mice were immunized twiceby subcutaneous injections. Control mice were left untreated
(control). IgG, IgG1, and IgG2a antibody titers were de-
termined in the sera of the immunized mice. IgG and IgG1
antibody titers to Gag were approximately 100-fold higher
in VLPH[G] immunized mice than in mice immunized with
VLPs containing fusion-defective VSV-G or lacking VSV-G
(Fig. 4B). VLPH[G] immunized mice also had T cells
recognizing an immunodominant peptide in Gag p24CA as
demonstrated by IFN-γ ELISPOT assay (Fig. 4C). The
IFN-γ ELISPOT response was lower in VLPH-immunized
mice. Interestingly, cellular immune responses induced by
VLPs pseudotyped with the fusion-defective mutant of
VSV-G also seemed to be reduced in comparison to those
induced by VLPH[G]. To further exclude nonspecific stimu-
lation of immune responses by VSV-G leading to increased
IFN-γ production, mice were also immunized with VSV-G
vesicles [G]. These vesicles were prepared exactly the same
way as the VLPs and contained similar amounts of VSV-G
as determined by Western blot analyses (data not shown).
IFN-γ ELISPOT responses to HIV antigens remained
undetectable in mice immunized with VSV-G vesicles
(Fig. 4C).
In the initial monkey study, animals were immunized
seven times over a period of 65 weeks. Since a shorter
immunization schedule would facilitate all subsequent
Fig. 3. Viral loads and percentage of CD4-positive cells in unvaccinated monkeys (A, C, E; control) or monkeys vaccinated with lipid–DNA (A, C, E), single cycle
immunodeficiency virus vaccines (SCIV; B, D, F), or VSV-G pseudotyped VLPs (VLP[G]; B, D, F). All monkeys were challenged with SIVmac239 at 69 weeks after
the first immunization. CD3+CD4+ cells are shown as percent of baseline levels ranging from 28 to 46%.
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four monkeys was immunized with VLP[G] six times during
a 28 week period. In Western blot analyses, the VLP[G]
preparation displayed a similar ratio of Gag and Env
proteins as previously observed for SCIV (Kuate et al.,
2003) (data not shown). Two control monkeys were
immunized with VSV-G in the absence of SIV antigens
([G]) after adjusting the amount of VSV-G in Western blot
analyses to the VSV-G content of VLP[G] (data not shown).
Three of the four immunized animals developed anti-
bodies to Gag and Env (Figs. 5A, C). The ELISPOT assay,
however, remained negative at most of the time points
analyzed (Figs. 5E, F). Four weeks after the last
immunization, monkeys were challenged with SIVmac239by the tonsillar route. The mean peak viremia was
approximately five-fold lower in the immunized monkeys
than in the control monkeys. After logarithmic transforma-
tion of the peak viral RNA levels, this difference was
statistically significant (t test: P = 0.048) (Figs. 6A, B), but
set point RNA levels were in the same range in both
groups. The cell-associated viral load levels in the PBMCs
(Figs. 6C, D) paralleled the results obtained for the viral
RNA levels. Determination of cell-associated viral load
levels in the lymph nodes of the monkeys 2 and 6 weeks
after challenge did not reveal obvious differences between
the two groups (data not shown). An anamnestic antibody
response was observed in the immunized monkeys, but not
in control animals (Figs. 5A, B). Positive ELISPOT
Fig. 4. Immunogenicity of VSV-G-pseudotyped VLPs in mice. VLPs were
prepared by cotransfection of HIV-1 gag-pol and env expression plasmids
(VLPH), while adding a VSV-G expression plasmid led to production of VSV-G-
pseudotyped VLPs (VLPH[G]). VLPH[Gmut]: VLPs pseudotyped with a fusion-
defective mutant of VSV-G. [G]: VSV-G containing vesicles prepared by
transfection of the VSV-G expression plasmid without HIV-1 expression
plasmids. The different VLPs were pelleted through a 20% sucrose cushion and
analyzed by Western blot with antibodies to HIV-1 Gag and Env and VSV-G
(A). VLPs and pseudotyped VLPs were normalized for RTcontent and groups of
mice were immunized subcutaneously twice. (B) Log antibody titers to Gag 1
week after the second immunization. The mean and standard deviation of two
experiments with different VLP preparations including six mice per group in
each experiment are shown. P values were calculated by an ANOVA test on
ranks. (C) Stimulation of T cells by immundominant HIV-1 peptides 1 week
after the second immunization. The IFN-γ ELISPOT assay represents the result
of two independent experiments each with 5 to 6 mice per group. P values were
calculated by an ANOVA test on ranks. SFU: IFN-γ spot forming units. Control:
unvaccinated control mice. aMean and standard deviation of five to six mice
from one experiment.
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groups. During the follow-up period of 36 weeks, the
percentage of CD4-positive T cells declined below 50% ofthe prechallenge values in one of the vaccinated monkeys
and 3 of the monkeys of the control group (Figs. 6E, F).
Discussion
Our findings in mice indicate that incorporation of VSV-G
into immunodeficiency virus-derived, noninfectious VLPs
increases humoral and cellular immune responses to immuno-
deficiency virus antigens. In particular, incorporation of VSV-G
into the VLPs led to 100-fold higher Gag antibody titers. Using
a fusion-defective mutant of VSV-G, the stimulatory effect of
VSV-G on antibody titers and IFN-ELISPOT response was
reduced. Thus, fusion-active VSV-G might enhance intracyto-
plasmic delivery of components of the VLPs leading to
improved presentation on MHC molecules as previously
proposed for DNA vaccines coexpressing VSV-G and gag
(Marsac et al., 2002). Whether VSV-G also contributes to
enhanced immune responses by triggering innate immune
responses remains to be determined.
Efficient induction of both humoral and cellular immune
responses might explain the striking protection imparted by
VSV-G pseudotyped SIV particles in the long-term rhesus
monkey vaccination experiment. In the first experiment, three
out of four monkeys immunized with VSV-G pseudotyped SIV
particles, either in a noninfectious (VLP) or infectious (SCIV)
form, were able to control replication of the SIVmac239
challenge virus for almost one year, while two naive control
monkeys and two monkeys vaccinated with lipid–DNA
complexes maintained high viral loads throughout the obser-
vation period (Figs. 3A to D). The comparison of viral load
levels in monkeys challenged after SCIVor VLP immunization
did not provide any evidence that SCIV was superior to VLP.
This suggests that expression of viral antigens in the vaccinees
is not required. Given the potential risk of insertional
mutagenesis by integration of the SCIV proviral DNA into
the genome of host cells, VSV-G pseudotyped VLPs should be
safer. Use of codon-optimized expression plasmids for the
production of the VLPs as done in the mouse experiments
further avoids transfer of viral genomic sequences to the
vaccinee and emergence of replication-competent recombinants
(Wagner et al., 2000). Thus, pseudotyping VLPs with VSV-G is
a strategy that could possibly be used in humans.
The control of SIVmac239 replication in monkeys vaccinat-
ed with VSV-G pseudotyped VLPs was striking in this first
experiment given the prior reports of inefficacy of whole
inactivated viruses and conventional VLPs lacking VSV-G (Le
Grand et al., 1992; Lu et al., 1998; Stott, 1991), including our
own (Notka et al., 1999). Although prepared differently, the
VLP vaccine used in this study resembles the AT2-inactivated
virus particle vaccine (Arthur et al., 1998) in the sense that both
vaccines contain the full set of viral structural genes and
maintain a fusion-competent Env protein. Despite this similar-
ity, vaccination of rhesus monkeys with AT2-inactivated virus
particle vaccines did not lead to control of replication of the
SIVmac239 challenge virus (Lifson et al., 2002). Since the two
vaccines differ in the VSV-G content, incorporation of VSV-G
appears to contribute to efficacy. However, a short-term
Fig. 5. Antibody titers to SIV Gag (A, B) or SIV Env (C, D) and IFN-gamma ELISPOT responses after stimulation with an overlapping SIV Ca peptide pool (E, F) in
VLP[G]-vaccinated and control monkeys of the 2nd study at the indicated time points after the 1st immunization. Control monkeys either received supernatants from
VSV-G-transfected cultures [G] or were left untreated (control). The dotted lines separate the data obtained before and after challenge at 32 weeks after the first
immunization.
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viremia. Consistently, IFN-ELISPOT responses were only seen
in the long-term rhesus monkey vaccination experiment after
the last booster immunization. Thus, a prolonged immunization
schedule with extended resting periods between immunizations
seems to be important. Consistently, the booster immunization
at week 29 in the long-term vaccination experiment led to a
strong increase in Gag-specific antibodies, but additional
injections at week 33 and 37 had only minor effects. However,
we cannot exclude that differences in the precise composition of
the VLP[G] vaccine preparations or the genetic background of
the monkeys are responsible for the different outcomes of the
first and second vaccination experiment. Rhesus monkeys of
both studies were of Chinese origin. Previous typing of 44rhesus monkeys of Chinese origin for Mamu-A1 and B17
alleles did not reveal the Mamu-A*01 allele, while Mamu-B*17
was only rarely detected in these macaques after DNA sequence
analysis of amplified PCR-products (U.S., unpublished obser-
vation). Despite extensive typing and DNA-sequence analysis,
no other MHC-I alleles could be linked to disease progression in
Chinese macaques. Thus, the currently established MHC-typing
protocols do not allow to identify MHC class I alleles in
Chinese rhesus macaques associated with better containment.
However, higher set point viral load levels in the control
monkeys of the first study suggest increased susceptability of
these monkeys. Therefore, reduced efficacy in the second study
is unlikely to be due to increased stringency of the virus host
challenge system. Since the same challenge virus stock was
Fig. 6. Viral loads and percentage of CD4-positive cells normalized to baseline values in VLP[G]-vaccinated (A, C, E) and control (B, D, F) monkeys at the indicated
time points after challenge with SIVmac239 at 32 weeks after the first immunization. Control monkeys either received supernatants from VSV-G-transfected cultures
[G] or were left untreated (control).
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challenge virus can be excluded.
In our studies, the VSV-G pseudotyped SIV particles were
generated by transfection of the human 293T cell line and the
VLPs therefore also contain human cell surface proteins. Since
the challenge virus had been grown on rhesus monkey PBMCs,
immune effector mechanisms directed against human proteins
cannot be responsible for the protection observed. In addition,
vaccinated monkeys were able to control virus replication in the
absence of a sterilizing immunity. Since after one round of
infection the viruses produced in the infected animals wereentirely derived from the host, immune responses against
nonviral heterologous proteins cannot be a relevant effector
mechanism. However, human proteins could play a role during
the induction phase of the antiviral immune response by for
example providing costimulatory signals.
When evaluating vaccine efficacy, the stringency of the
challenge system deserves attention because similar vaccines
elicit different degrees of protection depending on the challenge
system used. For example, monkeys primed with DNA and
boosted with a MVA vaccine were able to control the
SHIV89.6-challenge virus (Amara et al., 2001) but in
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reduction of viral load during primary infection was achieved,
but set point RNA levels were not considerably reduced (Horton
et al., 2002). Like primary isolates of HIV-1, SIVmac239 is
highly neutralization-resistant and protection from this virus,
while probably more relevant, seems to be more difficult to
achieve than from SHIV89.6 (Desrosiers, 2004; Horton et al.,
2002). Although our vaccines were based on SIVmac239,
vaccine-induced neutralizing antibodies could only be detected
against SIVmac251, but not against SIVmac239. This is
consistent with the neutralization-resistant phenotype observed
for SIVmac239 (Puffer et al., 2002).
To assess immunity at a mucosal site, we used the tonsillar
route of infection (Stahl-Hennig et al., 1999). This route allows
a truly atraumatic application of the challenge virus, which is
difficult to confirm during rectal challenge. In contrast to rectal
challenges, which often result in incomplete take of the
challenge virus, tonsillar infection has been highly reproducible
in our hands. So far, a total of 8 monkeys exposed to
SIVmac239, 20 monkeys exposed to SIVmac251, and 28
monkeys exposed to a nef-deletion mutant of SIVmac239 by the
tonsillar route became infected. In comparison to intravenously
infected monkeys, we did not observe any evidence for an
attenuated course of tonsillar infection (Stahl-Hennig et al.,
1999, 2002; Tenner-Racz et al., 2004). In two ongoing
experiments, an additional 10 naive monkeys, which were
challenged with the same stock and dose of SIVmac239 by the
tonsillar route, developed viral RNA levels comparable to the
naive monkeys challenged in this study.
Despite the small number of animals in the long-term
vaccination experiment, an approximately 1000-fold reduction
in SIVmac239 set point RNA levels after immunization with
VSV-G-pseudotyped SIV particles seems to compare favorably
to the efficacy of other exogenous antigen and viral vector
vaccines tested in the SIVmac239 challenge model (Horton et
al., 2002; Lifson et al., 2002; Murphy et al., 2000; Wang et al.,
2000). Potential enhancing effects of prime-boost regimens or
adjuvants remain to be determined.
This study also suggests a note of caution to the use of VSV-
G pseudotyped lentiviral or retroviral vectors for in vivo gene
therapy. It is to be expected that strong immune responses are
induced against the vector particle, possibly limiting the transfer
efficacy and harboring the risk of hyperreactivity after repeated
administrations.
In the second monkey experiment, where we hastened the
vaccination schedule from 65 to 28 weeks, we observed less
protection in the VLP[G]-vaccinated monkeys. The initial
infection was similar in both experiments, and in both, reduced
peak viral loads during acute infection were noted in the
vaccines. But a reduction in set point and long-term resistance
was only observed in the 65-week vaccination protocol.
Although there could be variability within monkeys, we suspect
that the more rapid vaccination protocol limited the induction of
protective memory. Nevertheless, our observations that pseu-
dotyping with VSV-G improves immune response in mice, and
in one experiment led to substantial protection in SIV
challenged vaccines, raise questions on how the VLP[G]strategy can be improved. Current understanding of the
principles for strong cell-mediated immunity involves capture
of vaccine by dendritic cells, migration to the T cell areas of
lymphoid organs, and appropriate maturation. Therefore, it may
be important to enhance the delivery of VLPs to DCs and more
rigorously control the delivery of maturation stimuli with these
vaccines by providing appropriate adjuvants. Although our
results were raised with small numbers of animals, VSV-G-
mediated enhancement of antigen uptake and/or stimulation of
innate immune responses could be of broad interest in the
demanding HIV vaccine field and be a more widely applicable
approach to improve vaccines against other infectious diseases.
Materials and methods
Preparation of vaccines for rhesus monkey experiment
SCIVs and VSV-G pseudotyped SIV VLPs (VLP[G]) for the
long-term monkey experiment were prepared side by side. 293T
cells were transiently transfected with the plasmids SX2Δfrxn
and pVSV-G, as previously described for SCIVs (Kuate et al.,
2003). In case of SCIVs, the expression plasmid for the
complementing tRNA was also included. SX2Δfrxn contains
the SIVmac239 proviral genome with deletions in vif, vpr, vpx,
and nef and mutations in the primer binding site. The mutated
primer binding site blocks initiation of reverse transcription.
Transfection of SX2Δfrxn therefore leads to noninfectious SIV-
VLPs (Kuate et al., 2003). Cotransfection of an artificial tRNA
expression plasmid (X2-Lys3) that matches the mutated primer
binding site rescues the block (Hansen et al., 2001). This leads
to the production of infectious SIV particles, that can only
undergo a single cycle of replication (SCIV) because of the
defective primer binding site (Kuate et al., 2003). One day after
transfection, the FCS-containing medium was replaced by
serum-free AIM-V medium (Gibco-Invitrogen-Corp., Karls-
ruhe, Germany) and supernatants were collected and filtered
24 h later. The titer of SCIVs in the supernatant of the
transfected cells was determined on S-Magi cells (Chackerian et
al., 1995) and the reverse transcriptase activity of the SCIVand
VLP[G] preparation was determined by the RT easy kit (Roche
Diagnostics, Mannheim, Germany). To control for nonspecific
effects of VSV-G, supernatants of 293T cells transfected with
only the VSV-G expression plasmid ([G]) were also harvested
as described above. Western blot analyses with the monoclonal
antibody P5D4 directed against VSV-G (Sigma-Aldrich,
Taufkirchen, Germany) were used to adjust the amount of
VSV-G present in the VLP[G] and [G] preparations. The lipid–
DNA vaccine was prepared by complexing SX2Δfrxn with
DOTAP and cholesterol as described for DC-high complexes
(Nchinda et al., 2003).
Immunization and challenge of rhesus monkeys
Rhesus monkeys of Chinese origin were housed at the
German Primate Center in Göttingen. Handling of the monkeys
and collection of specimens were performed according to
institutional guidelines as described previously (Stahl-Hennig et
142 S. Kuate et al. / Virology 351 (2006) 133–144al., 1990). Two young adult rhesus monkeys (Macaca mulatta)
seronegative for SIV, D-type retroviruses, and STLV-1 were
used per group. Immunizations were done at weeks 0, 4, 8, 29,
33, 37, and 65. For subcutaneous injection of SCIV, 107
infectious units corresponding to 9 μg reverse transcriptase
(week 0, 4, 8), 1.42 μg (week 29, 33, 37) and 0.89 μg (week 65)
respectively were injected in a 10 ml total volume at three
different sites proxolateral of the inguinal regions. A VLP[G]
preparation containing the same amount of reverse transcriptase
was injected in the same way. The lipid–DNA vaccine was
injected intradermally at a dose of 25 μg (week 0, 4, 8) and
80 μg (week 29, 33, 37 and 65) in a volume of 1 ml distributed
to 10 sites with 100 μl each. Immunized monkeys were
challenged by the tonsillar route (Stahl-Hennig et al., 1999) at
week 69 along with two naive monkeys with approximately
6000 median tissue culture infectious doses (TCID50) of the
cell-free pathogenic SIVmac239 stock described previously
(Gundlach et al., 1998). In the second experiment, rhesus
monkeys (n = 4) received subcutaneous injections of VLP[G]
preparations containing 4 μg RT/ml at week 0, 4, 8, 20, 24, and
28 as described above. Two of the control monkeys received
injections of VSV-G containing supernatants ([G]) from
transfected 293T cells, two additional control monkeys were
left untreated. All monkeys of the second study were challenged
at week 32 as described for the first experiment.
Monitoring the course of infection in monkeys
Viral RNA levels in the plasma were determined by real-time
PCR as described (Hofmann-Lehmann et al., 2002). Antibodies
to the SIV polypeptides Env and Gag were determined by a
standard ELISA. Microtiter plates (Greiner) were coated
overnight with recombinant SIV gp130 (repository number
EVA 670, NIBSC) or recombinant SIV p27 (repository number
ARP 643, NIBSC) diluted in 0.1 M carbonate buffer (pH 9.6) to
0.4 μg/ml. After blocking, a 1:200 dilution of plasma sample
was added in duplicate and the plates were incubated for 3 h at
room temperature. Plates were washed and incubated with anti-
human IgG peroxidase conjugate (Jackson BioLab) and
developed with B substrate (Sigma).
For the determination of neutralizing antibodies against
VSV-G and SIVmac239 Env, 1:100 and 1:10 dilutions of sera
were used, respectively. The neutralization assay was performed
using VSV-G or SIV-Env-pseudotyped SIV-based vector
particles as previously described (Kuate et al., 2003). The
levels of neutralizing antibodies against SIVmac251 in the sera
of immunized and infected macaques were measured using a
yield reduction assay. Briefly, sera diluted 1:50 were incubated
with serial dilutions of SIVmac251 (25 μl serum, 25 μl virus,
six replicates per dilution) in U96 microtiter plates. After
mixing and incubation for 1 h at 37 °C, 150 μl of a C8166 cell
suspension (2000 cells) was added. After 7 days of incubation at
37 °C, the cultures were lysed and virus replication in individual
wells measured by a sensitive Gag-based antigen capture
ELISA. Wells giving OD values above threshold (mean of
uninfected wells + 5 × SD) were scored as positive and the
TCID50 for the virus in the presence of each serum wascalculated. The yield reduction for each sample was then
calculated as the virus titer in the absence of serum divided by
the titer in the presence of serum.
To determine SIV-specific T cell responses an IFN-γ,
ELISPOT assay was employed. Ninety-six-well plates (MILLI-
PORE, MAIP S4510) were coated with 1 μg/well of antihuman
IFN-γ monoclonal antibody (MABTECH, Sweden) overnight
at 4 °C. The plates were washed with PBS and blocked with
RPMI1640 containing 10% fetal calf serum (FCS) for 2 h at 37
°C. RPMI1640 medium was discarded from the plates and
freshly isolated peripheral blood mononuclear cells (PBMCs) in
ELISPOT medium (RPMI1640, 2 mM glutamine, 0.05 mM 2-
mercaptoethanol, 10% FCS and antibiotics) were added. For
antigenic stimulation, a pool of SIV Gag peptides (5 μg/ml
each) comprising a set of overlapping 20mers covering the
entire SIV p26 region (ARP714.1-229, Programme EVA,
NIBSC) was added. 1 μg/ml SEB (Staphylococcal Enterotoxin
B, SIGMA) served as positive control, medium alone as
negative control. PBMCs (2 × 105) were plated in triplicate and
incubated for 16–18 h at 37 °C in 5% CO2. Cells were then
removed and plates were washed with PBS-0.05% Tween-20
(PBST). Biotinylated anti-human IFN-γ detector antibody
(MABTECH, Sweden) was added (0.1 μg/well) and plates
were incubated for 2 h at 37 °C before being washed again with
PBST. Streptavidin alkaline phosphatase conjugate (MAB-
TECH) at 1:1000 in PBS/0.1% FCS was added and incubated
for 2 h at room temperature. After washing, spots were
developed with NBT/BCIP (LOEWE, Germany) solution
(25 μg NBT plus 15 μg BCIP in 0.1 M Tris–HCl pH 9.5 per
well) for 30 min. After washing with distilled water and air-
drying, spots were counted by using a BIOSYS 2000 ELISPOT
reader. The counts were normalized to 106 cells input. Results
were calculated as the number of spots in the presence of
peptides minus the spot number obtained with medium alone.
To be defined as a SIV positive response, the latter number of
spots had to be greater than 100 and twice that of the medium
control.
For analysis of lymphocyte surface markers, PBMCs were
prepared from blood by Ficoll-Paque gradient centrifugation
and the percentage of CD4+ T cells determined by FACS
analysis in a Coulter EPICS XL flow cytometer using anti-
human CD3-PE and anti-human CD4-FITC. The baseline value
for each monkey was established by averaging the results of
three independent analyses prior to SIVmac239 infection and all
following measurements were related to the individual baseline
values.
Immunization of mice
To prepare VSV-G pseudotyped HIV-1 VLPs (VLPH[G]), a
codon-optimized expression plasmid for HIV-1 gag-pol
(Wagner et al., 2000) was cotransfected into 293T cells with
an HIV-1 env (Helseth et al., 1990) and tat (Malim et al., 1988)
expression plasmid and pVSV-G or a codon-optimized
expression plasmid for VSV-G (GeneArt, Regenburg, Ger-
many). VLPs lacking VSV-G (VLPH) were prepared by
omitting the VSV-G expression plasmid from the transfection
143S. Kuate et al. / Virology 351 (2006) 133–144reaction. As a control, pVSV-G was transfected into 293T cells
without HIV-1 expression plasmids. A fusion-defective mutant
of the codon-optimized VSV-G expression plasmid was
constructed by mutating the glutamine at position 117 to
asparagine as previously described for wild type VSV-G (Whitt
et al., 1990).
VLPs were harvested from serum-free medium as described
above for SIV VLPs and pelleted through a 20% sucrose
cushion by ultracentrifugation. Pellets were resuspended in PBS
prior to determination of RT-activity and Western blot analyses
with an antibody to VSV-G, HIV-1 Env, or an SIV antiserum
(S1604) crossreacting with HIV-1 Gag. In two independent
experiments, groups of five to six mice were immunized
subcutaneously with VLPs containing 1 μg RT at week 0 and 5.
Sera and spleen cells were harvested 1 week after the booster
immunization. Gag antibodies were quantified by an endpoint
dilution ELISA assay (in duplicate) on samples from individual
animals essentially as described previously (Wild et al., 2004).
Interferon-γ ELISPOT assays was performed as described. In
the first experiment, the number of ELISPOTs was determined
for six individual mice, in the second experiment, two pools of
spleen cells from 2 to 3 mice each were analyzed in triplicates.
The means and the standard deviations were calculated from all
the 12 data points. The mouse experiments were performed
blinded and were unmasked only after having measured the
immune responses.
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